Waldenstrom Macroglobulinemia

News

Frontline Therapy With RCVP has Similar Outcomes to Bendamustine-Rituximab in Patients With Treatment-Naïve WM

01/05/2022

Data from a real-world population-based analysis of frontline therapy with bendamustine-rituximab in patients with TN WM were presented at the 2021 ASH Annual Meeting to evaluate outcomes in TN-WM patients comparing BR with the combination of...

Data from a real-world...

01/05/2022

Oncology

Test Your Knowledge

Quiz: What is the First FDA Approved Therapy for WM?

12/22/2021

True or false: Ibrutinib, a BTK inhibitor, is not the first FDA approved therapy for WM.

True or false: Ibrutinib, a BTK...

12/22/2021

Oncology

Test Your Knowledge

Quiz: Is ASCT a Feasible Treatment Option for Patients With WM?

12/22/2021

True or false: ASCT is a feasible treatment option for patients with relapsed WM.

True or false: ASCT is a...

12/22/2021

Oncology

Videos

Dr Treon Highlights Mavorixafor Plus Ibrutinib for Patients With WM

12/16/2021

Steven P. Treon, MD, MA, PhD, discusses preliminary clinical data from a phase 1b study of mavorixafor in combination with ibrutinib for patients with WM with MYDD88 and CXCR4 mutations. These data were presented at the 2021 ASH Annual...

Steven P. Treon, MD, MA, PhD,...

12/16/2021

Oncology

Test Your Knowledge

Quiz: Is This Triplet Combo Effective for R/R WM?

11/17/2021

True or false: When used a second-line therapy, bendamustine, rituximab, and bortezomib, is not an effective treatment for patients with R/R WM.

True or false: When used a...

11/17/2021

Oncology

News

Triplet Therapy Found Effective, Well-Tolerated in R/R WM

11/17/2021

A phase 2 trial found that bendamustine, rituximab, and bortezomib, used a second-line therapy, is an effective and well-tolerated salvage treatment for patients with R/R WM; these data were presented at the 2021 ASH Annual Meeting.

A phase 2 trial found that...

11/17/2021

Oncology

Test Your Knowledge

Quiz: Which Treatment Shows Continued Efficacy in TN and R/R WM?

11/10/2021

Which treatment demonstrated sustained efficacy in TN and R/R WM after a 2-year follow-up period?

Which treatment demonstrated...

11/10/2021

Oncology

News

Tirabrutinib Shows Continued Efficacy in TN, R/R WM

11/10/2021

A report on 2 years of follow-up data from a phase 2 study found tirabrutinib continued to show efficacy in patients with TN or R/R WM; these findings were presented at the 2021 Annual ASH Meeting.

A report on 2 years of follow-up...

11/10/2021

Oncology